<description>&lt;div&gt; &lt;strong&gt;Show notes&lt;/strong&gt; &lt;br&gt;
&lt;br&gt;
To learn more about the 10th anniversary of the first FDA biosimilar approval, &lt;a href="https://www.centerforbiosimilars.com/view/from-amjevita-to-zarxio-a-decade-of-us-biosimilar-approvals"&gt;click here&lt;/a&gt;. &lt;br&gt;
To learn more about how much biosimilars have saved so far, &lt;a href="https://www.centerforbiosimilars.com/view/aam-report-generics-and-biosimilars-savings-reach-445-billion-in-2023-part-1"&gt;click here&lt;/a&gt;. &lt;br&gt;
To read more about Josh's views on the pharmaceutical landscape in 2025, &lt;a href="https://www.pharmexec.com/view/the-shifting-pharmacy-landscape-in-2025"&gt;click here&lt;/a&gt;. &lt;br&gt;
&lt;br&gt;

&lt;/div&gt;
</description>

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?

Josh Canavan, head of pharmacy at RazorMetrics, provides insights into why, despite the substantial savings biosimilars offer, they still represent only 23% of the overall biologics market.

Not So Different: A Podcast from The Center for Biosimilars

S7 Ep3: How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

S7 Ep3: How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

Description